Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H-H Brackmann

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
AIDS (London, England)|August 17, 1999
Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patientsR P Woitas, J K Rockstroh, I Beier, et al.
Human Genetics|January 24, 1998
Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII proteinR Schwaab, J Oldenburg, M R Lalloz, et al.
Thrombosis and Haemostasis|July 15, 2000
Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study GroupT C Abshire, H H Brackmann, I Scharrer, et al.
The New England Journal of Medicine|October 26, 1989
Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrateK Schimpf, H H Brackmann, W Kreuz, et al.
The New England Journal of Medicine|April 9, 1987
Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusionsK Schimpf, P M Mannucci, W Kreutz, et al.
Thrombosis and Haemostasis|August 1, 1995
Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised studyH H Brackmann, R Egbring, A Ferster, et al.
Deutsche Medizinische Wochenschrift (1946)|September 7, 2002
[Do polymorphisms of the SDF1 and CCR2b genes modify the course of hepatitis C or HIV/HCV co-infection?]R P Woitas, G Ahlenstiel, A Iwan, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1986
Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIIIY Sultan, G C White, A Aronstam, et al.
Infection|January 1, 1995
Male-to-female transmission of HIV in a cohort of hemophiliacs--frequency, risk factors and effect of sexual counselingJ K Rockstroh, S Ewig, T Bauer, et al.
British Journal of Haematology|July 1, 1997
Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapyJ Oldenburg, E M Quenzel, U Harbrecht, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
AIDS (London, England)|August 17, 1999
Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patientsR P Woitas, J K Rockstroh, I Beier, et al.
Human Genetics|January 24, 1998
Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII proteinR Schwaab, J Oldenburg, M R Lalloz, et al.
Thrombosis and Haemostasis|July 15, 2000
Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study GroupT C Abshire, H H Brackmann, I Scharrer, et al.
The New England Journal of Medicine|October 26, 1989
Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrateK Schimpf, H H Brackmann, W Kreuz, et al.
The New England Journal of Medicine|April 9, 1987
Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusionsK Schimpf, P M Mannucci, W Kreutz, et al.
Thrombosis and Haemostasis|August 1, 1995
Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised studyH H Brackmann, R Egbring, A Ferster, et al.
Deutsche Medizinische Wochenschrift (1946)|September 7, 2002
[Do polymorphisms of the SDF1 and CCR2b genes modify the course of hepatitis C or HIV/HCV co-infection?]R P Woitas, G Ahlenstiel, A Iwan, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1986
Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIIIY Sultan, G C White, A Aronstam, et al.
Infection|January 1, 1995
Male-to-female transmission of HIV in a cohort of hemophiliacs--frequency, risk factors and effect of sexual counselingJ K Rockstroh, S Ewig, T Bauer, et al.
British Journal of Haematology|July 1, 1997
Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapyJ Oldenburg, E M Quenzel, U Harbrecht, et al.
Pageof 14